相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1
Dafne C. A. Quixabeira et al.
ONCOIMMUNOLOGY (2022)
Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data
Tugce Kutuk et al.
CANCERS (2022)
Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma
Tomer Meirson et al.
JAMA NETWORK OPEN (2022)
A Correlative Study Between IVIM-DWI Parameters and the Expression Levels of Ang-2 and TKT in Hepatocellular Carcinoma
Jing Zheng et al.
FRONTIERS IN ONCOLOGY (2021)
CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? – Authors' reply
Dean A Fennell et al.
LANCET ONCOLOGY (2021)
Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models
Helena Mumblat et al.
LUNG CANCER (2021)
FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer
Luckson Mathieu et al.
ONCOLOGIST (2021)
Use of preclinical models for malignant pleural mesothelioma
Marie Shamseddin et al.
THORAX (2021)
Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform
Erkko Ylosmaki et al.
MOLECULAR THERAPY-ONCOLYTICS (2021)
Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model
Mariangela Garofalo et al.
PHARMACEUTICS (2021)
Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study
Luka Brcic et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach
Daniela Lisini et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Polymer Coated Oncolytic Adenovirus to Selectively Target Hepatocellular Carcinoma Cells
Mariangela Garofalo et al.
PHARMACEUTICS (2021)
Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome
Shaokang Ma et al.
ONCOIMMUNOLOGY (2020)
Metabolic rewiring and redox alterations in malignant pleural mesothelioma
Loredana Urso et al.
BRITISH JOURNAL OF CANCER (2020)
Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor
Lukasz Kuryk et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Neoadjuvant checkpoint blockade for cancer immunotherapy
Suzanne L. Topalian et al.
SCIENCE (2020)
Preclinical Models of Malignant Mesothelioma
Joseph R. Testa et al.
FRONTIERS IN ONCOLOGY (2020)
Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives
Steven G. Gray et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Arnaud Scherpereel et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
Luca Cantini et al.
FRONTIERS IN ONCOLOGY (2020)
Oncolytic herpesvirus therapy for mesothelioma - A phase I/IIa trial of intrapleural administration of HSV1716
Sarah J. Danson et al.
LUNG CANCER (2020)
Cross-Species Proteomics Identifies CAPG and SBP1 as Crucial Invasiveness Biomarkers in Rat and Human Malignant Mesothelioma
Joelle S. Nader et al.
CANCERS (2020)
A RANDOMISED OPEN-LABEL PHASE I/II STUDY ADDING ONCOS-102 TO PEMETREXED/CISPLATIN IN PATIENTS WITH UNRESECTABLE MALIGNANT PLEURAL MESOTHELIOMA-12 MONTH ANALYSIS OF BIOMARKERS AND CLINICAL OUTCOMES
Magnus Jaderberg et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy
Jung-Ho Kim et al.
IMMUNE NETWORK (2020)
Quantification and functional evaluation of CD40L production from the adenovirus vector ONCOS-401
Lukasz Kuryk et al.
CANCER GENE THERAPY (2019)
Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks
Lukasz Kuryk et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Extra-pleural pneumonectomy
Leonardo Duranti et al.
JOURNAL OF THORACIC DISEASE (2019)
The role of apoptosis defects in malignant mesothelioma pathogenesis with an impact on prognosis and treatment
Vasiliki Galani et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy
Rosa Sottile et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Prolonged retention of liposomes in the pleural cavity of normal mice and high tumor distribution in mice with malignant pleural effusion, after intrapleural injection
A. Marazioti et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2019)
Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma
Lukasz Kuryk et al.
JOURNAL OF MEDICAL VIROLOGY (2019)
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Sebastian Chretien et al.
CANCERS (2019)
A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial
Robert A. Belderbos et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Association Between VEGF Expression and Diffusion Weighted Imaging in Several Tumors-A Systematic Review and Meta-Analysis
Hans-Jonas Meyer et al.
DIAGNOSTICS (2019)
Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
Emanuela Cova et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2019)
Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model
Lukasz Kuryk et al.
ONCOIMMUNOLOGY (2019)
Inhibition of EZH2 methyltransferase decreases immunoediting of mesothelioma cells by autologous macrophages through a PD-1-dependent mechanism
Malik Hamaidia et al.
JCI INSIGHT (2019)
Malignant Mesothelioma and Its Non-Asbestos Causes
Richard L. Attanoos et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis
Ulrich M. Lauer et al.
CLINICAL CANCER RESEARCH (2018)
Experimental Model of Human Malignant Mesothelioma in Athymic Mice
Didier J. Colin et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment
M. Garofalo et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model
Lukasz Kuryk et al.
JOURNAL OF MEDICAL VIROLOGY (2018)
HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome
Simona di Martino et al.
ONCOGENE (2018)
CONFIRM: a double-blind, placebo controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial
Dean A. Fennell et al.
TRIALS (2018)
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma
Vasiliki Panou et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Scientific Advances and New Frontiers in Mesothelioma Therapeutics
Luciano Mutti et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Combination immune checkpoint blockade as an effective therapy for mesothelioma
Vanessa S. Fear et al.
ONCOIMMUNOLOGY (2018)
The Akt pathway in oncology therapy and beyond (Review)
George Mihai Nitulescu et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2018)
Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human
Joachim G. J. V. Aerts et al.
CLINICAL CANCER RESEARCH (2018)
Immunoregulatory functions of VISTA
Elizabeth C. Nowak et al.
IMMUNOLOGICAL REVIEWS (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
Elly Marcq et al.
ONCOTARGET (2017)
A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma
Cristian Capasso et al.
ONCOIMMUNOLOGY (2017)
Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)
Astero Klampatsa et al.
CANCERS (2017)
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102-Support for clinical studies on advanced cancer treatment
Lukasz Kuryk et al.
PLOS ONE (2017)
Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism
Chiara De Santi et al.
SCIENTIFIC REPORTS (2017)
Checkpoint Blockade in Lung Cancer and Mesothelioma
Lysanne A. Lievense et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Immunotherapy and radiation therapy for malignant pleural mesothelioma
Evan W. Alley et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2017)
Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis
Monica Khunger et al.
JCO PRECISION ONCOLOGY (2017)
Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma
A. Napolitano et al.
ONCOGENE (2016)
Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline Bap1 Mutations
Yuwaraj Kadariya et al.
CANCER RESEARCH (2016)
Encapsulation in a rapid-release liposomal formulation enhances the anti-tumor efficacy of pemetrexed in a murine solid mesothelioma-xenograft model
Noha Essam Eldin et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model
Lukasz Kuryk et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
Igor Puzanov et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Oncolytic Adenovirus Loaded with L-carnosine as Novel Strategy to Enhance the Antitumor Activity
Mariangela Garofalo et al.
MOLECULAR CANCER THERAPEUTICS (2016)
PD-L1 expression in human cancers and its association with clinical outcomes
Xin Wang et al.
ONCOTARGETS AND THERAPY (2016)
Characterization of preneoplastic and neoplastic rat mesothelial cell lines: the involvement of TETs, DNMTs, and 5-hydroxymethylcytosine
David Roulois et al.
ONCOTARGET (2016)
Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers
Tuuli Ranki et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells
Rosanna Mezzapelle et al.
SCIENTIFIC REPORTS (2016)
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
Anna C. Bibby et al.
EUROPEAN RESPIRATORY REVIEW (2016)
Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data
Dmitriy Zamarin et al.
HUMAN GENE THERAPY (2015)
Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed
Hidenori Ando et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors
Karishma R. Rajani et al.
VIRUSES-BASEL (2015)
Reactive oxygen species a double-edged sword for mesothelioma
Serena Benedetti et al.
ONCOTARGET (2015)
Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer
L. Vassilev et al.
ONCOIMMUNOLOGY (2015)
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
Prasad S. Adusumilli et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Gregory L. Beatty et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization
Tuuli Ranki et al.
ONCOIMMUNOLOGY (2014)
Molecular pathogenesis of malignant mesothelioma
Yoshitaka Sekido
CARCINOGENESIS (2013)
The Basic Principles of Chimeric Antigen Receptor Design
Michel Sadelain et al.
CANCER DISCOVERY (2013)
Pegylated liposomal doxorubicin in malignant pleural mesothelioma: a possible guardian for long-term survival
Paul Zarogoulidis et al.
ONCOTARGETS AND THERAPY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
DNA repair systems in malignant mesothelioma
Dimitrios Toumpanakis et al.
CANCER LETTERS (2011)
Asbestos, Lung Cancers, and Mesotheliomas From Molecular Approaches to Targeting Tumor Survival Pathways
Nicholas H. Heintz et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2010)
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. E. Van Schil et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy
Y. Watanabe et al.
ONCOGENE (2010)
mTOR Mediates Survival Signals in Malignant Mesothelioma Grown as Tumor Fragment Spheroids
Shannon M. Wilson et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2008)
A conditional mouse model for malignant mesothelioma
Johan Jongsma et al.
CANCER CELL (2008)
Treatment of Malignant Pleural Mesothelioma with Carboplatin, Liposomized Doxorubicin, and Gemcitabine A Phase II Study
Gunnar Hillerdal et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
BTS statement on malignant mesothelioma in the UK, 2007
John Wiggins
THORAX (2007)
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results
Federico Rea et al.
LUNG CANCER (2007)
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors
Eilon D. Kirson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Functional characterization of OX40 expressed on human CD8+ T cells
Tomoko Fujita et al.
IMMUNOLOGY LETTERS (2006)
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma
GL Ceresoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma
K Hiraoka et al.
BRITISH JOURNAL OF CANCER (2006)
Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma
V Gupta et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Medical progress - Advances in malignant mesothelioma
BWS Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A mouse model recapitulating molecular features of human mesothelioma
DA Altomare et al.
CANCER RESEARCH (2005)
SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure
P Cacciotti et al.
CANCER RESEARCH (2005)
Activation of p38 MAP kinase by asbestos in rat mesothelial cells is mediated by oxidative stress
WA Swain et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2004)
Avidin/biotin-liposome system injected in the pleural space for drug delivery to mediastinal lymph nodes
LA Medina et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature:: A novel mechanism for IL-21
C Jackaman et al.
JOURNAL OF IMMUNOLOGY (2003)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma
A Hughes et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Accelerated progression of asbestos-induced mesotheliomas in heterozygous p53+/- mice
CA Vaslet et al.
TOXICOLOGICAL SCIENCES (2002)
分享论文
